Therapy using a combination of raloxifene and alendronate
US7579333B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2005 |
| Grant date | Aug 25, 2009 |
| Priority date | — |
| Expiry date | Nov 25, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of treating bone disease including, but not limited to, osteoporosis, metastatic bone disease, or Paget's disease, by administering a combination of raloxifene and alendronate in a manner that mitigates the formation of ulcerative adverse events.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.